Cargando…

Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study

BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is a major cause of cancer morbidity and mortality in Eastern Africa. The majority of patients with ESCC in Eastern Africa present with advanced disease at the time of diagnosis. Several palliative interventions for ESCC are currently in use with...

Descripción completa

Detalles Bibliográficos
Autores principales: Buckle, Geoffrey C., Mrema, Alita, Mwachiro, Michael, Ringo, Yona, Selekwa, Msiba, Mulima, Gift, Some, Fatma F., Mmbaga, Blandina T., Mody, Gita N., Zhang, Li, Paciorek, Alan, Akoko, Larry, Ayuo, Paul, Burgert, Stephen, Bukusi, Elizabeth, Charles, Anthony, Chepkemoi, Winnie, Chesumbai, Gladys, Kaimila, Bongani, Kenseko, Aida, Kibwana, Kitembo Salum, Koech, David, Macharia, Caren, Moirana, Ezekiel N., Mushi, Beatrice Paul, Mremi, Alex, Mwaiselage, Julius, Mwanga, Ally, Ndumbalo, Jerry, Nvakunga, Gissela, Ngoma, Mamsau, Oduor, Margaret, Oloo, Mark, Opakas, Jesse, Parker, Robert, Seno, Saruni, Salima, Ande, Servent, Furaha, Wandera, Andrew, Westmoreland, Kate D., White, Russell E., Williams, Brittney, Mmbaga, Elia J., Van Loon, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772224/
https://www.ncbi.nlm.nih.gov/pubmed/35045815
http://dx.doi.org/10.1186/s12885-021-09124-5
_version_ 1784635798668181504
author Buckle, Geoffrey C.
Mrema, Alita
Mwachiro, Michael
Ringo, Yona
Selekwa, Msiba
Mulima, Gift
Some, Fatma F.
Mmbaga, Blandina T.
Mody, Gita N.
Zhang, Li
Paciorek, Alan
Akoko, Larry
Ayuo, Paul
Burgert, Stephen
Bukusi, Elizabeth
Charles, Anthony
Chepkemoi, Winnie
Chesumbai, Gladys
Kaimila, Bongani
Kenseko, Aida
Kibwana, Kitembo Salum
Koech, David
Macharia, Caren
Moirana, Ezekiel N.
Mushi, Beatrice Paul
Mremi, Alex
Mwaiselage, Julius
Mwanga, Ally
Ndumbalo, Jerry
Nvakunga, Gissela
Ngoma, Mamsau
Oduor, Margaret
Oloo, Mark
Opakas, Jesse
Parker, Robert
Seno, Saruni
Salima, Ande
Servent, Furaha
Wandera, Andrew
Westmoreland, Kate D.
White, Russell E.
Williams, Brittney
Mmbaga, Elia J.
Van Loon, Katherine
author_facet Buckle, Geoffrey C.
Mrema, Alita
Mwachiro, Michael
Ringo, Yona
Selekwa, Msiba
Mulima, Gift
Some, Fatma F.
Mmbaga, Blandina T.
Mody, Gita N.
Zhang, Li
Paciorek, Alan
Akoko, Larry
Ayuo, Paul
Burgert, Stephen
Bukusi, Elizabeth
Charles, Anthony
Chepkemoi, Winnie
Chesumbai, Gladys
Kaimila, Bongani
Kenseko, Aida
Kibwana, Kitembo Salum
Koech, David
Macharia, Caren
Moirana, Ezekiel N.
Mushi, Beatrice Paul
Mremi, Alex
Mwaiselage, Julius
Mwanga, Ally
Ndumbalo, Jerry
Nvakunga, Gissela
Ngoma, Mamsau
Oduor, Margaret
Oloo, Mark
Opakas, Jesse
Parker, Robert
Seno, Saruni
Salima, Ande
Servent, Furaha
Wandera, Andrew
Westmoreland, Kate D.
White, Russell E.
Williams, Brittney
Mmbaga, Elia J.
Van Loon, Katherine
author_sort Buckle, Geoffrey C.
collection PubMed
description BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is a major cause of cancer morbidity and mortality in Eastern Africa. The majority of patients with ESCC in Eastern Africa present with advanced disease at the time of diagnosis. Several palliative interventions for ESCC are currently in use within the region, including chemotherapy, radiation therapy with and without chemotherapy, and esophageal stenting with self-expandable metallic stents; however, the comparative effectiveness of these interventions in a low resource setting has yet to be examined. METHODS: This prospective, observational, multi-center, open cohort study aims to describe the therapeutic landscape of ESCC in Eastern Africa and investigate the outcomes of different treatment strategies within the region. The 4.5-year study will recruit at a total of six sites in Kenya, Malawi and Tanzania (Ocean Road Cancer Institute and Muhimbili National Hospital in Dar es Salaam, Tanzania; Kilimanjaro Christian Medical Center in Moshi, Tanzania; Tenwek Hospital in Bomet, Kenya; Moi Teaching and Referral Hospital in Eldoret, Kenya; and Kamuzu Central Hospital in Lilongwe, Malawi). Treatment outcomes that will be evaluated include overall survival, quality of life (QOL) and safety. All patients (≥18 years old) who present to participating sites with a histopathologically-confirmed or presumptive clinical diagnosis of ESCC based on endoscopy or barium swallow will be recruited to participate. Key clinical and treatment-related data including standardized QOL metrics will be collected at study enrollment, 1 month following treatment, 3 months following treatment, and thereafter at 3-month intervals until death. Vital status and QOL data will be collected through mobile phone outreach. DISCUSSION: This study will be the first study to prospectively compare ESCC treatment strategies in Eastern Africa, and the first to investigate QOL benefits associated with different treatments in sub-Saharan Africa. Findings from this study will help define optimal management strategies for ESCC in Eastern Africa and other resource-limited settings and will serve as a benchmark for future research. TRIAL REGISTRATION: This study was retrospectively registered with the ClinicalTrials.gov database on December 15, 2021, NCT05177393. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-09124-5.
format Online
Article
Text
id pubmed-8772224
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87722242022-01-20 Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study Buckle, Geoffrey C. Mrema, Alita Mwachiro, Michael Ringo, Yona Selekwa, Msiba Mulima, Gift Some, Fatma F. Mmbaga, Blandina T. Mody, Gita N. Zhang, Li Paciorek, Alan Akoko, Larry Ayuo, Paul Burgert, Stephen Bukusi, Elizabeth Charles, Anthony Chepkemoi, Winnie Chesumbai, Gladys Kaimila, Bongani Kenseko, Aida Kibwana, Kitembo Salum Koech, David Macharia, Caren Moirana, Ezekiel N. Mushi, Beatrice Paul Mremi, Alex Mwaiselage, Julius Mwanga, Ally Ndumbalo, Jerry Nvakunga, Gissela Ngoma, Mamsau Oduor, Margaret Oloo, Mark Opakas, Jesse Parker, Robert Seno, Saruni Salima, Ande Servent, Furaha Wandera, Andrew Westmoreland, Kate D. White, Russell E. Williams, Brittney Mmbaga, Elia J. Van Loon, Katherine BMC Cancer Study Protocol BACKGROUND: Esophageal squamous cell carcinoma (ESCC) is a major cause of cancer morbidity and mortality in Eastern Africa. The majority of patients with ESCC in Eastern Africa present with advanced disease at the time of diagnosis. Several palliative interventions for ESCC are currently in use within the region, including chemotherapy, radiation therapy with and without chemotherapy, and esophageal stenting with self-expandable metallic stents; however, the comparative effectiveness of these interventions in a low resource setting has yet to be examined. METHODS: This prospective, observational, multi-center, open cohort study aims to describe the therapeutic landscape of ESCC in Eastern Africa and investigate the outcomes of different treatment strategies within the region. The 4.5-year study will recruit at a total of six sites in Kenya, Malawi and Tanzania (Ocean Road Cancer Institute and Muhimbili National Hospital in Dar es Salaam, Tanzania; Kilimanjaro Christian Medical Center in Moshi, Tanzania; Tenwek Hospital in Bomet, Kenya; Moi Teaching and Referral Hospital in Eldoret, Kenya; and Kamuzu Central Hospital in Lilongwe, Malawi). Treatment outcomes that will be evaluated include overall survival, quality of life (QOL) and safety. All patients (≥18 years old) who present to participating sites with a histopathologically-confirmed or presumptive clinical diagnosis of ESCC based on endoscopy or barium swallow will be recruited to participate. Key clinical and treatment-related data including standardized QOL metrics will be collected at study enrollment, 1 month following treatment, 3 months following treatment, and thereafter at 3-month intervals until death. Vital status and QOL data will be collected through mobile phone outreach. DISCUSSION: This study will be the first study to prospectively compare ESCC treatment strategies in Eastern Africa, and the first to investigate QOL benefits associated with different treatments in sub-Saharan Africa. Findings from this study will help define optimal management strategies for ESCC in Eastern Africa and other resource-limited settings and will serve as a benchmark for future research. TRIAL REGISTRATION: This study was retrospectively registered with the ClinicalTrials.gov database on December 15, 2021, NCT05177393. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-09124-5. BioMed Central 2022-01-19 /pmc/articles/PMC8772224/ /pubmed/35045815 http://dx.doi.org/10.1186/s12885-021-09124-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Buckle, Geoffrey C.
Mrema, Alita
Mwachiro, Michael
Ringo, Yona
Selekwa, Msiba
Mulima, Gift
Some, Fatma F.
Mmbaga, Blandina T.
Mody, Gita N.
Zhang, Li
Paciorek, Alan
Akoko, Larry
Ayuo, Paul
Burgert, Stephen
Bukusi, Elizabeth
Charles, Anthony
Chepkemoi, Winnie
Chesumbai, Gladys
Kaimila, Bongani
Kenseko, Aida
Kibwana, Kitembo Salum
Koech, David
Macharia, Caren
Moirana, Ezekiel N.
Mushi, Beatrice Paul
Mremi, Alex
Mwaiselage, Julius
Mwanga, Ally
Ndumbalo, Jerry
Nvakunga, Gissela
Ngoma, Mamsau
Oduor, Margaret
Oloo, Mark
Opakas, Jesse
Parker, Robert
Seno, Saruni
Salima, Ande
Servent, Furaha
Wandera, Andrew
Westmoreland, Kate D.
White, Russell E.
Williams, Brittney
Mmbaga, Elia J.
Van Loon, Katherine
Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study
title Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study
title_full Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study
title_fullStr Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study
title_full_unstemmed Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study
title_short Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study
title_sort treatment outcomes of esophageal cancer in eastern africa: protocol of a multi-center, prospective, observational, open cohort study
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772224/
https://www.ncbi.nlm.nih.gov/pubmed/35045815
http://dx.doi.org/10.1186/s12885-021-09124-5
work_keys_str_mv AT bucklegeoffreyc treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT mremaalita treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT mwachiromichael treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT ringoyona treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT selekwamsiba treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT mulimagift treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT somefatmaf treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT mmbagablandinat treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT modygitan treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT zhangli treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT paciorekalan treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT akokolarry treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT ayuopaul treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT burgertstephen treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT bukusielizabeth treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT charlesanthony treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT chepkemoiwinnie treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT chesumbaigladys treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT kaimilabongani treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT kensekoaida treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT kibwanakitembosalum treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT koechdavid treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT machariacaren treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT moiranaezekieln treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT mushibeatricepaul treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT mremialex treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT mwaiselagejulius treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT mwangaally treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT ndumbalojerry treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT nvakungagissela treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT ngomamamsau treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT oduormargaret treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT oloomark treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT opakasjesse treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT parkerrobert treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT senosaruni treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT salimaande treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT serventfuraha treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT wanderaandrew treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT westmorelandkated treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT whiterusselle treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT williamsbrittney treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT mmbagaeliaj treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT vanloonkatherine treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy
AT treatmentoutcomesofesophagealcancerineasternafricaprotocolofamulticenterprospectiveobservationalopencohortstudy